WELCOME TO The Biotechnology REPORT
Laboratory of Genetics (BIOZ)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
PharmAbcine | December 08, 2020
PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020.
Equillium, Inc. | February 17, 2022
Equillium, Inc. a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has acquired Bioniz Therapeutics, Inc., a privately held clinical-stage biotechnology company. Bioniz developed its novel structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from its proprietary product discovery platform. The Bioniz lead product candidates are multi-specifi...
CELL AND GENE THERAPY
Enzychem Lifesciences | March 03, 2022
Enzychem Lifesciences a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee. Composed of four eminent physicians, its mission is to support and guide corporate activities including technology transfer for its lead compound, EC-18, seeking strategic partnerships, and preparing U.S. phase 3 clinical trials to successfully commercialize EC-18.
After the completion of its phase 2 U.S. clinical trial with EC-18 in Chemoradiation&ndash...
Fauna Bio | April 01, 2022
A biotechnology business pioneering comparative, computational, and translational genomics, Fauna Bio, announced collaboration with the University of Wisconsin OshKosh to speed the translation of human treatments identified via research into extreme mammal adaption. Fauna Bio's sponsorship of UW Oshkosh with $500,000 expands the University's capability for biomedical partnerships and helps promote the University as a destination for academics exploring innovative animal models and ...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE